ANAPTYSBIO, INC. Earnings Per Share (Basic)
ANAPTYSBIO, INC. (ANAB) reported Earnings Per Share (Basic) of $4.52 per share for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-09-21
- ANAPTYSBIO, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$1.84.
- ANAPTYSBIO, INC. earnings per share, basic for the quarter ending 2025-09-30 was $0.54.
- ANAPTYSBIO, INC. earnings per share, basic for the quarter ending 2025-06-30 was -$1.34.
- ANAPTYSBIO, INC. earnings per share, basic for the quarter ending 2025-03-31 was -$1.28.
- ANAPTYSBIO, INC. earnings per share, basic for fiscal 2025 was -$0.46.
- ANAPTYSBIO, INC. earnings per share, basic for fiscal 2024 was -$5.12.
- ANAPTYSBIO, INC. earnings per share, basic for fiscal 2023 was -$6.08.
- ANAPTYSBIO, INC. earnings per share, basic for fiscal 2022 was -$4.57.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.52 10-KT · filed 2026-09-21 | |||
| 2026-03-31 | -$1.84 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$0.46 10-KT · filed 2026-09-21 | |||
| 2025-09-30 | $0.54 10-Q · filed 2025-11-04 | -$2.16 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | -$1.34 10-Q · filed 2025-08-06 | -$2.62 10-KT · filed 2026-09-21 | ||
| 2025-03-31 | -$1.28 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$5.12 10-KT · filed 2026-09-21 | |||
| 2024-09-30 | -$1.14 10-Q · filed 2025-11-04 | -$4.46 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | -$1.71 10-Q · filed 2025-08-06 | -$3.35 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -$1.64 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | -$6.08 10-K · filed 2026-03-03 | |||
| 2023-09-30 | -$1.41 10-Q · filed 2024-11-05 | -$4.49 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | -$1.50 10-Q · filed 2024-08-05 | -$3.08 10-Q · filed 2024-08-05 | ||
| 2023-03-31 | -$1.58 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$4.57 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$1.18 10-Q · filed 2023-11-02 | -$3.64 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | -$1.15 10-Q · filed 2023-08-07 | -$2.46 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$1.31 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$2.11 10-K · filed 2024-03-11 | |||
| 2021-09-30 | -$0.24 10-Q · filed 2022-11-08 | -$0.92 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | -$0.02 10-Q · filed 2022-08-08 | -$0.68 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$0.66 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | -$0.73 10-K · filed 2023-03-01 | |||
| 2020-09-30 | -$0.87 10-Q · filed 2021-11-04 | -$1.96 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | -$0.79 10-Q · filed 2021-08-09 | -$1.09 10-Q · filed 2021-08-09 | ||
| 2019-12-31 | -$0.75 10-K · filed 2020-03-02 | -$3.60 10-K · filed 2022-03-07 | ||
| 2019-09-30 | -$1.15 10-K · filed 2020-03-02 | |||
| 2019-06-30 | -$0.89 10-K · filed 2020-03-02 | |||
| 2019-03-31 | -$0.82 10-K · filed 2020-03-02 | |||
| 2018-12-31 | -$0.64 10-K · filed 2020-03-02 | -$2.50 10-K · filed 2020-03-02 | ||
| 2018-09-30 | -$0.66 10-K · filed 2020-03-02 | |||
| 2018-06-30 | -$0.57 10-K · filed 2020-03-02 | |||
| 2018-03-31 | -$0.63 10-K · filed 2020-03-02 | |||
| 2017-12-31 | -$0.30 10-K · filed 2019-02-28 | -$1.52 10-K · filed 2019-02-28 | ||
| 2017-09-30 | -$0.45 10-K · filed 2019-02-28 | -$0.58 derived: net income ÷ weighted average shares · filed 2019-02-28 | -$1.24 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$0.13 10-K · filed 2019-02-28 | -$0.79 10-Q · filed 2017-08-10 | ||
| 2017-03-31 | -$0.75 10-K · filed 2019-02-28 | |||
| 2016-12-31 | -$1.73 10-K · filed 2018-03-05 | -$1.62 10-K · filed 2018-03-05 | ||
| 2016-09-30 | -$0.42 10-K · filed 2018-03-05 | $0.46 derived: net income ÷ weighted average shares · filed 2018-03-05 | $0.00 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $0.07 10-K · filed 2018-03-05 | $0.00 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | -$0.34 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |